Last reviewed · How we verify
NCT02103387
Five Sessions Intervention to Facilitate Adaptation to Breast Cancer
NA trial testing Cognitive Behavioral Training in Breast Cancer in 194 participants. Completed in 25 February 2014.
25 February 2014
Quick facts
| Lead sponsor | University of Miami |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | supportive care |
| Enrollment | 194 |
| Start date | 2 January 2007 |
| Primary completion | 25 February 2014 |
| Estimated completion | 25 February 2014 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Cognitive Behavioral Training
- Relaxation Training
- Health Education Control
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
Sponsor
University of Miami
Who can join
Adults 21 to 75, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To test the effects of 2 different 5-wk stress management interventions (cognitive behavioral training or relaxation training) vs. a time-matched 5-wk health education condition on psychosocial adaptation and physiological adaptation in women being treated for breast cancer. Participants assigned to either of the stress management conditions will show improved psychosocial adaptation and physiological adaptation compared to those assigned to the health education condition.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Brief cognitive-behavioral and relaxation training interventions for breast cancer: A randomized controlled trial.
Gudenkauf LM, Antoni MH, Stagl JM, Lechner SC, et al · · 2015 · cited 76× · PMID 25939017 · DOI 10.1037/ccp0000020 -
The effects of a randomized trial of brief forms of stress management on RAGE-associated S100A8/A9 in patients with breast cancer undergoing primary treatment.
Taub CJ, Lippman ME, Hudson BI, Blomberg BB, et al · · 2019 · cited 26× · PMID 30633331 · DOI 10.1002/cncr.31965 -
Effects of brief stress management interventions on distress and leukocyte nuclear factor kappa B expression during primary treatment for breast cancer: A randomized trial.
Diaz A, Taub CJ, Lippman ME, Antoni MH, et al · · 2021 · cited 19× · PMID 33611132 · DOI 10.1016/j.psyneuen.2021.105163 -
Brief relaxation training is associated with long-term endocrine therapy adherence among women with breast cancer: post hoc analysis of a randomized controlled trial.
Ream ME, Walsh EA, Jacobs JM, Taub C, et al · · 2021 · cited 15× · PMID 34410568 · DOI 10.1007/s10549-021-06361-x -
Relationships Between Serum Cortisol, RAGE-Associated s100A8/A9 Levels, and Self-Reported Cancer-Related Distress in Women With Nonmetastatic Breast Cancer.
Taub CJ, Diaz A, Blomberg BB, Jutagir DR, et al · · 2022 · cited 7× · PMID 35980780 · DOI 10.1097/psy.0000000000001109 -
Brief Post-Surgical Stress Management Reduces Pro-Inflammatory Cytokines in Overweight and Obese Breast Cancer Patients Undergoing Primary Treatment.
Ream M, Saez-Clarke E, Taub C, Diaz A, et al · · 2022 · cited 5× · PMID 35638415 · DOI 10.31083/j.fbl2705148 -
Does the Broaden-and-Build Theory Explain Reduction in Social Disruption After a Brief Relaxation Intervention for Women With Breast Cancer Undergoing Treatment?
Fisher HM, Taub CJ, Lechner SC, Heller AS, et al · · 2022 · cited 3× · PMID 35987554 · DOI 10.1016/j.beth.2022.04.002 -
Brief Post-Surgical Stress Management Intervention Effects on Positive Psychological Well-Being and Self-Efficacy in Women Being Treated With Adjuvant Endocrine Therapy for Hormone-Receptor Positive Breast Cancer.
Ream M, Taub CJ, Amonoo HL, Walsh EA, et al · · 2025 · cited 2× · PMID 40846861 · DOI 10.1002/pon.70267
Verify or expand the search:
- PubMed search for NCT02103387
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other University of Miami trials
Trials by the same sponsor.
- NCT06003712 — Exploring the Effect of Mindfulness on Quality of Life (QoL) in Spinal Cord Injury (SCI) · NA · not yet recruiting
- NCT06077071 — MRIdian "RADAR" Trial · NA · not yet recruiting
- NCT07472413 — Alternate Pre-med in Anti-Cluster of Differentiation 20 (CD20) Pilot Project · Phase 3 · not yet recruiting
- NCT07322289 — Antibiotic-coated Braided Suture Study · NA · not yet recruiting
- NCT07469592 — eHealth Mindfulness-based Music Therapy Intervention for Patients Undergoing Stem Cell Transplantation · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02103387 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Miami
- Last refreshed: 10 November 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02103387.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing